AZN Latest Press Releases

-- October 30, 2026 --

Enhertu Wins 2026 International Prix Galien Award for Best Biotechnology Product Business Wire 7:00 AM

AstraZeneca results: 9M and Q3 2026 Business Wire 7:00 AM

-- October 29, 2026 --

2027 Could Finally Be the Year Cancer Is on the Ropes! Globe Newswire 9:10 PM

-- October 28, 2026 --

AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing Business Wire 8:00 AM

-- October 27, 2026 --

Enhertu Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer Business Wire 3:30 AM

-- October 26, 2026 --

Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades Globe Newswire 1:12 PM

Gabelli To Host 8th Annual Healthcare Symposium Globe Newswire 8:00 AM

-- October 25, 2026 --

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 Business Wire 11:35 AM

TAGRISSO (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Business Wire 11:30 AM

-- October 24, 2026 --

IMFINZI (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial Business Wire 10:35 AM

Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer Business Wire 10:30 AM

-- October 22, 2026 --

ZEGFROVY (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations Business Wire 8:10 AM

-- October 20, 2026 --

TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week Business Wire 9:00 AM

-- October 19, 2026 --

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI (durvalumab), TAGRISSO (osimertinib) and savolitinib Business Wire 7:00 AM

-- October 8, 2026 --

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology PRNewswire 9:01 AM

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology Globe Newswire 9:00 AM

-- October 5, 2026 --

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts Business Wire 12:01 PM

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics Business Wire 7:00 AM

-- October 2, 2026 --

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway Business Wire 2:30 AM

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway in Combination with Ivonescimab Across Multiple Tumor Types Business Wire 2:30 AM

-- September 29, 2026 --

High-Stakes October has these Biotechs Entering Crucial Stretch Globe Newswire 12:12 PM

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics Business Wire 8:07 AM

-- September 25, 2026 --

Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer Business Wire 7:00 AM

-- September 18, 2026 --

Enhertu Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer Business Wire 8:00 AM

-- September 13, 2026 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial Business Wire 9:55 PM

TAGRISSO (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial Business Wire 9:47 PM

Enhertu Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial Business Wire 9:45 PM

-- September 8, 2026 --

IMFINZI (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer Business Wire 9:00 AM

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials Business Wire 7:50 AM

-- September 4, 2026 --

ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Business Wire 7:03 PM

-- September 1, 2026 --

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY (sunvozertinib) for lung cancer Business Wire 7:00 AM

Enhertu Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer Business Wire 2:30 AM

-- August 27, 2026 --

TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Business Wire 7:00 AM

-- August 26, 2026 --

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer's Biggest Opportunity Globe Newswire 9:20 AM

TROPION-Urothelial04 Phase 3 Trial of Datroway Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer Business Wire 7:00 AM

-- August 19, 2026 --

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does. Globe Newswire 8:56 AM

-- August 17, 2026 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial Business Wire 7:30 AM

TAGRISSO (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Business Wire 7:00 AM

Enhertu Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial Business Wire 2:30 AM

-- August 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN PRNewswire 11:02 PM

-- August 4, 2026 --

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies PRNewswire 6:15 AM

-- July 31, 2026 --

Datroway Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy Business Wire 2:30 AM

-- July 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN PRNewswire 10:01 AM

-- July 28, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN Globe Newswire 5:27 PM

-- July 27, 2026 --

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers Business Wire 7:05 AM

AstraZeneca results: H1 and Q2 2026 Business Wire 7:00 AM

-- July 24, 2026 --

Enhertu Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer Business Wire 7:00 AM

-- July 23, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN PRNewswire 10:01 AM

-- July 22, 2026 --

AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm Business Wire 8:59 PM

-- July 21, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN Globe Newswire 12:50 PM

-- July 16, 2026 --

AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky PRNewswire 10:07 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN PRNewswire 10:00 AM

-- July 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN Globe Newswire 4:54 PM

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN) Globe Newswire 10:12 AM

-- July 13, 2026 --

AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN) Business Wire 10:07 AM

-- July 10, 2026 --

AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca PRNewswire 9:00 AM

-- July 9, 2026 --

AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN) PRNewswire 8:58 PM

-- July 6, 2026 --

As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models PRNewswire 8:55 AM

The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel PRNewswire 8:45 AM

-- July 1, 2026 --

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO for NSCLC PRNewswire 9:00 PM

-- June 29, 2026 --

Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors Business Wire 2:30 AM

-- June 26, 2026 --

Datroway Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy Business Wire 7:00 AM

-- June 24, 2026 --

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care Business Wire 9:00 AM

-- June 22, 2026 --

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology Globe Newswire 8:30 AM

-- June 12, 2026 --

TRUQAP (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer Business Wire 6:44 PM

-- June 5, 2026 --

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History PRNewswire 8:55 AM

-- June 2, 2026 --

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial Business Wire 8:00 AM

-- June 1, 2026 --

IMFINZI (durvalumab) plus IMJUDO (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial Business Wire 8:00 AM